COLLABORATION AGREEMENTS (Tables)

6 Months Ended

Jun. 30, 2012

Deferred Revenue

payment under its former collaboration agreement with Pfizer. Deferred revenue consisted of the following:

	June 30, 2012		December 31, 2011
Current portion:
Deferred revenue from Astellas	$	29,024	$	23,747
Deferred revenue from Pfizer		5,486		36,015
Total	$	34,510	$	59,762
Long-term portion:
Deferred revenue from Astellas	$	29,024	$	47,494
Deferred revenue from Pfizer		—		36,015
Total	$	29,024	$	83,509

Schedule Of Collaboration Revenue

Collaboration revenue recognized with respect to the Astellas Collaboration Agreement and the former collaboration agreement with Pfizer consisted of the following:

	Three months ended				Six months ended
	June 30,				June 30,
	2012		2011		2012		2011
Collaboration revenue from Astellas	$	7,256	$	6,795	$	13,193	$	12,500
Collaboration revenue from Pfizer		35,656		9,004		66,544		18,008
Total	$	42,912	$	15,799	$	79,737	$	30,508

Development And Commercialization Cost-Sharing Payments Receivable

The Company recorded development cost-sharing payments from Astellas and Pfizer, and corresponding reductions in research and development expenses as follows:

	Three months ended June 30,				Six months ended June 30,
	2012		2011		2012		2011
Development cost-sharing payments from Astellas	$	14,013	$	11,226	$	28,128	$	21,113
Development cost-sharing payments from Pfizer		362		2,988		1,689		7,903
Total	$	14,375	$	14,214	$	29,817	$	29,016

The Company recorded commercialization cost-sharing payments (to) from Astellas and Pfizer, and corresponding (increases) reductions in selling, general and administrative expenses as follows:

	Three months ended June 30,				Six months ended June 30,
	2012		2011		2012			2011
Commercialization cost-sharing payments from (to) Astellas	$	146	$	526	$	(670	)	$	458
Commercialization cost-sharing payments from Pfizer		5		23		9			36
Total	$	151	$	549	$	(661	)	$	494